Enanta Pharmaceuticals (ENTA) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to -$18.6 million.
- Enanta Pharmaceuticals' Income towards Parent Company rose 3507.51% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 2941.25%. This contributed to the annual value of -$81.8 million for FY2025, which is 2941.25% up from last year.
- Latest data reveals that Enanta Pharmaceuticals reported Income towards Parent Company of -$18.6 million as of Q3 2025, which was up 3507.51% from -$18.3 million recorded in Q2 2025.
- Enanta Pharmaceuticals' Income towards Parent Company's 5-year high stood at -$18.3 million during Q2 2025, with a 5-year trough of -$39.1 million in Q2 2023.
- For the 5-year period, Enanta Pharmaceuticals' Income towards Parent Company averaged around -$28.3 million, with its median value being -$28.6 million (2024).
- Per our database at Business Quant, Enanta Pharmaceuticals' Income towards Parent Company crashed by 50391.34% in 2021 and then surged by 4199.92% in 2024.
- Quarter analysis of 5 years shows Enanta Pharmaceuticals' Income towards Parent Company stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then increased by 16.61% to -$18.6 million in 2025.
- Its Income towards Parent Company stands at -$18.6 million for Q3 2025, versus -$18.3 million for Q2 2025 and -$22.6 million for Q1 2025.